Edgewise Therapeutics (EWTX) Projected to Post Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Edgewise Therapeutics to post earnings of ($0.4677) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.04. On average, analysts expect Edgewise Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Trading Up 16.5%

NASDAQ:EWTX opened at $44.71 on Wednesday. Edgewise Therapeutics has a 12 month low of $12.30 and a 12 month high of $48.40. The stock has a 50 day moving average of $38.82 and a two-hundred day moving average of $33.77. The firm has a market cap of $4.81 billion, a P/E ratio of -26.93 and a beta of 0.30.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EWTX. Truist Financial set a $52.00 price target on Edgewise Therapeutics in a research note on Wednesday, May 6th. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Edgewise Therapeutics in a research note on Tuesday, June 16th. Evercore restated an “outperform” rating and issued a $55.00 price objective on shares of Edgewise Therapeutics in a report on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Edgewise Therapeutics in a report on Friday, July 17th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $66.00 target price on shares of Edgewise Therapeutics in a research note on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.75.

Insiders Place Their Bets

In other news, insider Alan J. Russell sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $39.41, for a total transaction of $7,882,000.00. Following the transaction, the insider directly owned 24,555 shares in the company, valued at $967,712.55. The trade was a 89.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 21.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edgewise Therapeutics

Institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Edgewise Therapeutics by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company’s stock valued at $963,000 after buying an additional 2,463 shares during the period. Jones Financial Companies Lllp acquired a new position in Edgewise Therapeutics in the first quarter valued at approximately $47,000. Goldman Sachs Group Inc. lifted its holdings in Edgewise Therapeutics by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 366,644 shares of the company’s stock valued at $8,066,000 after acquiring an additional 19,753 shares during the last quarter. Strs Ohio purchased a new position in Edgewise Therapeutics in the first quarter worth approximately $84,000. Finally, Creative Planning grew its position in Edgewise Therapeutics by 29.4% in the second quarter. Creative Planning now owns 16,910 shares of the company’s stock worth $222,000 after acquiring an additional 3,837 shares during the period.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.